Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Abeona Therapeutics (ABEO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 671,802
  • Shares Outstanding, K 47,310
  • Annual Sales, $ 840 K
  • Annual Income, $ -27,320 K
  • 36-Month Beta 1.26
  • Price/Sales 802.55
  • Price/Cash Flow N/A
  • Price/Book 3.96

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.85 +3.61%
on 07/19/18
17.25 -16.81%
on 06/27/18
-2.20 (-13.29%)
since 06/20/18
3-Month
13.85 +3.61%
on 07/19/18
22.00 -34.77%
on 04/23/18
-6.55 (-31.34%)
since 04/20/18
52-Week
7.01 +104.71%
on 08/15/17
22.75 -36.92%
on 10/11/17
+4.60 (+47.18%)
since 07/20/17

Most Recent Stories

More News
Implied Volatility Surging for Abeona Therapeutics (ABEO) Stock Options

Abeona Therapeutics (ABEO) needs investors to pay close attention to the stock based on moves in the options market lately.

ABEO : 14.35 (+1.06%)
Newman Ferrara LLP Announces Corporate Governance Investigation of Abeona Therapeutics Inc. - ABEO

Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of stockholders of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO) into potential...

ABEO : 14.35 (+1.06%)
57% Sales Growth, Top-Notch Partners At Overlooked Gene and Cell Therapy Issue ORGS

Cell and gene therapy development hitting fever pitch globally as more products enter phase 3 and late-stage testing. Manufacturing remains the issue, and many companies turning to outsourced manufacturing...

BLUE : 180.35 (+0.78%)
ABEO : 14.35 (+1.06%)
AXON : 2.46 (-4.28%)
Cancer Treatment Breakthroughs Providing Boost for Biotech Market

MarketNewsUpdates.com News Commentary

SGMO : 15.10 (+0.33%)
JNCE : 7.57 (-2.70%)
ABEO : 14.35 (+1.06%)
MBRX : 1.75 (+0.57%)
NKTR : 48.73 (-0.71%)
BMY : 56.71 (+0.30%)
Abeona Therapeutics Announces Upcoming Presentation at Jefferies 2018 Global Healthcare Conference

Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced...

ABEO : 14.35 (+1.06%)
Fanconi Anemia: H1 2018 Pipeline Review Covering Abeona Therapeutics, Genethon and Novartis - ResearchAndMarkets.com

The "Fanconi Anemia - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.

ABEO : 14.35 (+1.06%)
Abeona Therapeutics Announces Opening of Commercial Gene & Cell Therapy Manufacturing Facility in Ohio

-- The Elisa Linton Center for Rare Disease Therapies to support development of advanced gene and cell therapies for treatment of serious rare diseases

ABEO : 14.35 (+1.06%)
Analysis: Positioning to Benefit within Avadel Pharmaceuticals, Abeona Therapeutics, BanColombia S.A, Aercap Holdings N.V, Kite Realty Group Trust, and Credicorp -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Avadel Pharmaceuticals PLC....

KRG : 16.63 (-1.48%)
BAP : 229.57 (+1.25%)
AVDL : 6.82 (-1.87%)
ABEO : 14.35 (+1.06%)
CIB : 47.78 (+0.02%)
AER : 55.53 (+0.02%)
Abeona Therapeutics Provides Clinical Update on MPS IIIA Gene Therapy Trial at the 21st Annual ASGCT Meeting

-- 11 subjects enrolled through > 4,200 days cumulative follow up

ABEO : 14.35 (+1.06%)
Abeona Therapeutics Reports First Quarter 2018 Financial Results and Business Highlights

NEW YORK and CLEVELAND, May 11, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for...

ABEO : 14.35 (+1.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade ABEO with:

Business Summary

Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., is based in Dallas, United States.

See More

Key Turning Points

2nd Resistance Point 14.78
1st Resistance Point 14.57
Last Price 14.35
1st Support Level 14.17
2nd Support Level 13.98

See More

52-Week High 22.75
Fibonacci 61.8% 16.74
Fibonacci 50% 14.88
Last Price 14.35
Fibonacci 38.2% 13.02
52-Week Low 7.01

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar